No association of MDM2 SNP309 with risk of glioblastoma and prognosis.
The MDM2 SNP309 variant has been shown to increase MDM2 expression and to be associated with tumor formation. In glioblastomas, the P53/MDM2 pathway is of crucial importance and MDM2 amplification is related to poor prognosis. However, we show here that MDM2 SNP309 is not associated with glioblastoma risk, and is not a prognostic factor.
El Hallani
Soufiane
S
INSERM, U711, Biologie des Interactions Neurones & Glie, Paris 75013, France.
Marie
Yannick
Y
Idbaih
Ahmed
A
Rodero
Mathieu
M
Boisselier
Blandine
B
Laigle-Donadey
Florence
F
Ducray
François
F
Delattre
Jean-Yves
JY
Sanson
Marc
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics*; D001932:Brain Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D020022:Genetic Predisposition to Disease; D005909:Glioblastoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics*; D012016:Reference Values; D012307:Risk Factors; D016019:Survival Analysis
D014408:Biomarkers, Tumor; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2